Literature DB >> 24436106

Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance.

Karla C S Queiroz1, Kun Shi, JanWillem Duitman, Hella L Aberson, Johanna W Wilmink, Carel J M van Noesel, Dick J Richel, C Arnold Spek.   

Abstract

Protease activated receptor (PAR)-1 expression in tumor cells is associated with disease progression and overall survival in a variety of cancers of epithelial origin; however, the importance of PAR-1 in the tumor microenvironment remains unexplored. Utilizing an orthotopic pancreatic cancer model in which tumor cells are PAR-1 positive whereas stromal cells are PAR-1 negative, we show that PAR-1 expression in the microenvironment drives progression and induces chemoresistance of pancreatic cancer. PAR-1 enhances monocyte recruitment into the tumor microenvironment by regulating monocyte migration and fibroblast dependent chemokine production thereby inducing chemoresistance. Overall, our data identify a novel role of PAR-1 in the pancreatic tumor microenvironment and suggest that PAR-1 may be an attractive target to reduce drug resistance in pancreatic cancer.
© 2014 UICC.

Entities:  

Keywords:  chemoresistance; macrophage; microenvironment; protease activated receptors

Mesh:

Substances:

Year:  2014        PMID: 24436106     DOI: 10.1002/ijc.28726

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  31 in total

1.  MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.

Authors:  Peter C Lucas; Linda M McAllister-Lucas; J Randall McAuley; Kelly M Bailey; Prasanna Ekambaram; Linda R Klei; Heejae Kang; Dong Hu; Tanner J Freeman; Vincent J Concel; Nathaniel E Hubel; Jia-Ying Lloyd Lee; Hanna B Klei; Jing Cheng; Preethiya Sekar; Rachel E Bridwell; Lidija Covic
Journal:  Oncogene       Date:  2019-08-16       Impact factor: 9.867

2.  Dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer in mice.

Authors:  Kun Shi; Helene Damhofer; Joost Daalhuisen; Marieke Ten Brink; Dick J Richel; C Arnold Spek
Journal:  Mol Med       Date:  2017-02-06       Impact factor: 6.354

3.  Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion.

Authors:  Yi Yang; Amanda Stang; Patrick G Schweickert; Nadia A Lanman; Erin N Paul; Brett P Monia; Alexey S Revenko; Joseph S Palumbo; Eric S Mullins; Bennett D Elzey; Edith M Janssen; Stephen F Konieczny; Matthew J Flick
Journal:  Cancer Res       Date:  2019-05-02       Impact factor: 12.701

4.  Protease-activated receptor-1 impedes prostate and intestinal tumor progression in mice.

Authors:  G N Adams; B K Sharma; L Rosenfeldt; M Frederick; M J Flick; D P Witte; L O Mosnier; E Harmel-Laws; K A Steinbrecher; J S Palumbo
Journal:  J Thromb Haemost       Date:  2018-09-27       Impact factor: 5.824

5.  Rivaroxaban does not affect growth of human pancreatic tumors in mice.

Authors:  Anaum Maqsood; Yohei Hisada; Kenison B Garratt; Jonathon Homeister; Nigel Mackman
Journal:  J Thromb Haemost       Date:  2019-08-26       Impact factor: 5.824

Review 6.  Targeting PAR1: Now What?

Authors:  Robert Flaumenhaft; Karen De Ceunynck
Journal:  Trends Pharmacol Sci       Date:  2017-05-27       Impact factor: 14.819

Review 7.  Tissue Factor and Cancer: Regulation, Tumor Growth, and Metastasis.

Authors:  Yohei Hisada; Nigel Mackman
Journal:  Semin Thromb Hemost       Date:  2019-05-16       Impact factor: 4.180

Review 8.  Tissue factor: a neglected role in cancer biology.

Authors:  Haiyuan Li; Yang Yu; Lei Gao; Peng Zheng; Xiaolong Liu; Hao Chen
Journal:  J Thromb Thrombolysis       Date:  2022-06-28       Impact factor: 2.300

Review 9.  GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets.

Authors:  Krishna Sriram; Cristina Salmerón; Shu Z Wiley; Paul A Insel
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

10.  PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo.

Authors:  R Auvergne; C Wu; A Connell; S Au; A Cornwell; M Osipovitch; A Benraiss; S Dangelmajer; H Guerrero-Cazares; A Quinones-Hinojosa; S A Goldman
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.